Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oil gains 3% as US-Iran peace talks in stalemate
- Oppenheimer sees AI software winners as focus shifts to ROI
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
August 5, 2026 4:05 PM EDTNew CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:... More
